These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24969823)

  • 21. Regulatory issues related to functional foods and natural health products in Canada: possible implications for manufacturers of conjugated linoleic acid.
    Fitzpatrick KC
    Am J Clin Nutr; 2004 Jun; 79(6 Suppl):1217S-1220S. PubMed ID: 15159260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Thomson Reuters/West
    Issue Brief Health Policy Track Serv; 2011 Jan; ():1-39. PubMed ID: 21374841
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
    Berry MD
    Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
    [No Abstract]   [Full Text] [Related]  

  • 24. A compromise too far: a review of Canadian cases of direct-to-consumer advertising regulation.
    Lexchin J; Mintzes B
    Int J Risk Saf Med; 2014; 26(4):213-25. PubMed ID: 25420763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Over the counter drugs--a new era in Israel].
    Abadi-Korek I; Vaknin S; Marom E; Shemer J; Luxenburg O
    Harefuah; 2011 Jan; 150(1):29-32, 69, 68. PubMed ID: 21449153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Status of certain additional over-the-counter drug category II and III active ingredients--FDA. Final rule.
    Fed Regist; 1998 Apr; 63(77):19799-802. PubMed ID: 10179316
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Model competencies in regulatory therapeutic product assessment: Health Canada's good review guiding principles as a reviewing community's code of intellectual conduct.
    Lim RR
    Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):933-41. PubMed ID: 17290483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Over-the-counter sales of statins and other drugs for asymptomatic conditions.
    Tinetti ME
    N Engl J Med; 2008 Jun; 358(25):2728-32. PubMed ID: 18565867
    [No Abstract]   [Full Text] [Related]  

  • 31. Polypharmacy meets polyherbacy: pharmaceutical, over-the-counter, and natural health product use among Canadian adults.
    Votova K; Blais R; Penning MJ; Maclure MK
    Can J Public Health; 2013 May; 104(3):e222-8. PubMed ID: 23823886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Similar biological medicinal products containing recombinant human growth hormone: European regulation.
    Pavlovic M; Girardin E; Kapetanovic L; Ho K; Trouvin JH
    Horm Res; 2008; 69(1):14-21. PubMed ID: 18059081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors.
    Laeeque H; Boon H; Kachan N; Cohen JC; D'Cruz J
    BMC Health Serv Res; 2006 May; 6():63. PubMed ID: 16734916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scientific and legal viability of follow-on protein drugs.
    Dudzinski DM; Kesselheim AS
    N Engl J Med; 2008 Feb; 358(8):843-9. PubMed ID: 18287608
    [No Abstract]   [Full Text] [Related]  

  • 36. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Now you see it. Now you don't: fair balance and adequate provision in advertisements for drugs before and after the switch from prescription to over-the-counter.
    Faerber AE; Kreling DH
    Health Commun; 2012; 27(1):66-74. PubMed ID: 21745037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Viral safety of biological medicinal products].
    Stühler A; Blümel J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Oct; 57(10):1198-202. PubMed ID: 25123140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ophthalmic drug products for over-the-counter human use; proposed amendment of final monograph--FDA. Proposed rule.
    Fed Regist; 1998 Feb; 63(35):8888-90. PubMed ID: 10177740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Canadian approach to freedom of expression and the regulation of food and drug advertising.
    McNaughton EL; Goodridge CM
    Food Drug Law J; 2003; 58(3):521-36. PubMed ID: 14626988
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.